Bristol-Myers Squibb Company (BMY)

業務介紹

Bristol-Myers Squibb Company（百時美施貴寶公司）是一家全球性的生物製藥公司，從事發現、研發、授權、製造和銷售生物製藥產品。該公司提供用於血液學、腫瘤學、心血管學、免疫學、纖維化學、神經科學和新冠肺炎等疾病的產品。該公司的產品包括Revlimid（雷利莫德），一種口服免疫調節藥物，用於治療多發性骨髓瘤；Eliquis（愛力達），一種口服抑制劑，用於降低非瓣膜性心房顫動患者中中風/全身性栓塞的風險，以及用於治療深靜脈血栓形成/肺栓塞；Opdivo（奧維度），用於抗癌治療；Pomalyst/Imnovid（波瑪利斯特/伊諾維德），用於多發性骨髓瘤患者；以及Orencia（歐力實），用於成人活躍性風濕性關節炎和乾癬性關節炎患者。此外，該公司還提供Sprycel（斯普瑞克），用於治療染色體陽性慢性骨髓性白血病；Yervoy（伊維莫），用於治療無法手術切除或轉移性黑色素瘤患者；Abraxane（阿伯席），一種蛋白結合型化療產品；Reblozyl（瑞寶實），用於治療成年貝塔地中海貧血患者的貧血；以及Empliciti（艾普利西），用於治療多發性骨髓瘤。此外，該公司還提供Zeposia（澤波西亞），用於治療多發性硬化症的復發型；Breyanzi（布雷安茲），一種CD19導向的基因改造自體T細胞免疫療法，用於治療成年復發或難治性大B細胞淋巴瘤患者；Inrebic（因瑞必），一種口服激酶抑制劑，用於治療成年骨髓纖維化患者；以及Onureg（奧努瑞格），用於治療成年急性髓性白血病患者。該公司將產品銷售給批發商、分銷商、藥店、零售商、醫院、診所和政府機構。該公司以前被稱為Bristol-Myers Company（百時美施貴寶公司）。該公司成立於1887年，總部位於紐約州紐約市。

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

公司網址

https://www.bms.com